The short answer
L-arginine may lower blood pressure in some settings, while ropinirole can cause a pressure drop on standing. Review the combination with your clinician if you have dizziness, fainting or low blood pressure. Added harm from the exact pair has not been established.
What this answer covers
Oral L-arginine supplements. High-dose intravenous findings are not treated as equivalent to oral use.
- Supplement or preparation
- L-Arginine
- Medication ingredient
- ropinirole
The oral evidence is mixed
One small controlled study found a modest reduction in diastolic blood pressure after three weeks of high-dose oral L-arginine. Another found no significant pressure change after a single oral dose. These are different exposures and neither studied people taking ropinirole.
Why infusion results are different
In the dose-and-route study, a large intravenous dose lowered blood pressure, while the tested oral dose did not. An infusion result should not be used to predict the effect of an oral supplement.
Your symptoms and blood-pressure history matter
Ropinirole can cause low blood pressure on standing, especially during dose increases. Tell your prescriber about dizziness, near-fainting or fainting and about other medicines that affect blood pressure.
Plan use with the treating team
Bring the L-arginine product, dose and reason for use to your clinician. The evidence does not establish a safe combination dose or a protective spacing interval. Do not adjust ropinirole yourself based on an average blood-pressure change from a study.
Evidence and practical considerations
Side effects & toxicity
Variable oral L-arginine blood-pressure findings support caution in susceptible ropinirole users, without demonstrating combined symptomatic hypotension.
- Exact scope
- Oral L-arginine supplements. High-dose intravenous findings are not treated as equivalent to oral use. with Oral immediate-release ropinirole; hydrochloride salt expressed as equivalent free base in the inspected label.
- Medication form and route
- oral ropinirole; supplement preparation and route described in scope
- Timing or duration
- No exact-pair safe duration or protective spacing interval established.
What remains uncertain
- Small selected populations, different doses and durations, and no ropinirole co-use or orthostatic interaction endpoint.
Factors that may matter: orthostatic symptoms; low baseline blood pressure; ropinirole dose escalation.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral immediate-release ropinirole tablets for Parkinson disease or primary restless legs syndrome.
Ropinirole can cause somnolence, sudden sleep episodes and orthostatic hypotension. Concomitant sedating medicines or alcohol can increase sleepiness risk. CYP1A2 is its major metabolic enzyme; inhibitors and inducers may alter clearance. Ciprofloxacin increased exposure, whereas theophylline did not. Cigarette smokers had lower dose-normalized exposure than nonsmokers in a small RLS comparison.
How this applies: Exact oral ropinirole risk and metabolic context; section 11 justifies hydrochloride-to-free-base active-moiety identity only.
None of these ten supplement pairs is directly tested in this label. Cigarette smoking is not interchangeable with oral cannabis or isolated CBD; ciprofloxacin results are not caffeine results. No extended-release kinetic equivalence assumed.
Source 2: randomized placebo-controlled crossover study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 16 middle-aged men with hypercholesterolemia.
Diastolic blood pressure was 1.9 mm Hg lower relative to placebo; several hemodynamic responses changed, but peripheral resistance did not.
How this applies: Oral blood-pressure signal supporting caution, not proof of symptomatic combined hypotension.
No ropinirole and not an orthostatic-hypotension study; high oral dose and selected population.
Source 3: placebo-controlled pharmacokinetic-pharmacodynamic study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Eight healthy men.
Blood pressure and peripheral resistance fell with 30 g intravenously but were not significantly changed after 6 g orally or intravenously.
How this applies: Preserves dose and route distinctions and a relevant null oral result.
Small acute study, no ropinirole. Negative oral result cannot establish safety for chronic use or vulnerable patients.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources inspected and exact current claim adjudicated; no clinical review asserted. | |
| Research summary published |
Article revision: 09f4ab5bbc32578e
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.